|
Guest
|
Pharmacol Res. 2003 Jan;47(1):17-26. Related Articles, Links
Click here to read
Effects of polyphenolic fraction of silymarin on lipoprotein profile
in rats fed cholesterol-rich diets.
Skottova N, Vecera R, Urbanek K, Vana P, Walterova D, Cvak L.
Institute of Pharmacology, Medical Faculty, Palacky University,
Hnevotinska 3, 775 15 Olomouc, Czech Republic.
To study the influence of polymerised polyphenolics (PP), a fraction
of silymarin (SM), on lipids and oxidant status, rats were fed
high-cholesterol (1%), high-fat (10%) diets containing either lard fat
(LFD) rich in saturated/monounsaturated fatty acids, or currant oil
(COD) rich in polyunsaturated fatty acids. PP and SM were administered
as dietary supplements (0.1-0.5-1.0%) for 3 weeks. PP (1%) decreased
cholesterol (C) in VLDL (from 0.72+/-0.08 mmol l(-1) in LFD control to
0.35+/-0.07 mmol l(-1), P<0.01, and from 0.33+/-0.05 mmol l(-1) in COD
control to 0.09+/-0.02 mmol l(-1), P<0.001), and increased HDL-C/VLDL-C
ratio, however, without effect on the total plasma C and LDL-C. Liver C
content (LFD 19.32+/-1.50 micromol g(-1), COD 18.64+/-2.13 micromol
g(-1), N.S.) decreased after PP (1%) to 12.24+/-0.76 micromol g(-1),
P<0.01, and 8.78+/-0.95 micromol g(-1), P<0.001, respectively.
Triacylglycerols (TAG) in plasma and VLDL decreased after PP in the LFD
group only, which displayed higher TAG levels than the COD group.
Likewise, LFD caused a higher liver TAG content than did COD
(31.16+/-3.00 micromol g(-1) versus 17.31+/-1.48 micromol g(-1),
P<0.01), and PP (1%) decreased liver TAG only in rats fed LFD
(19.55+/-2.43 micromol g(-1), P<0.02). Blood glutathione (GSH) increased
after PP (1%) in the LFD group from 0.97+/-0.11 to 1.54+/-0.19 mmol
l(-1) (P<0.05) and in the COD group from 0.58+/-0.15 to 1.23+/-0.10 mmol
l(-1) (P<0.01), while liver GSH and plasma TBARS did not change. On
principle, effects of PP were dose-dependent and parallel to SM. These
results suggest that the polyphenolic fraction of SM positively modifies
lipoprotein profile, counteracts the development of fatty liver and
ameliorates an antioxidant status in circulation.
PMID: 12526857 [PubMed - indexed for MEDLINE] |
|
|
